Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparing Quality of Life in Smell and Taste Disorders With Other Chronic Conditions-A Narrative Review.

Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery·2026
Same author

Entrustable Professional Activity Framework Implementation and Impressions from U.S. and Canadian Pediatric Cardiology Training Programs.

Pediatric cardiology·2026
Same author

Evaluation of the CompreHensive geriAtRician-led MEdication Review (CHARMER) deprescribing intervention in hospital: protocol for a cluster randomised stepped-wedge trial.

BMJ open·2026
Same author

Safety, Efficacy, and Immunogenicity of a Multivalent Adjuvanted S. aureus Vaccine in Adults with Recent Skin And Soft Tissue Infections: An Observer-blind, Randomized, Placebo-controlled, Multinational Phase 1/2 Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

CUL3-Related Neurodevelopmental Disorder: Expanding the Prenatal Phenotype.

Prenatal diagnosis·2026
Same author

Fetal Macrocephaly: Prenatal Findings and Follow-Up in Cases With High Risk for Abnormal Outcome.

Prenatal diagnosis·2025
Same journal

Compound heterozygous variants in F7 gene causing severe factor VII deficiency without bleeding: A genotypic and laboratory analysis.

Blood cells, molecules & diseases·2026
Same journal

Propofol attenuates H<sub>2</sub>O<sub>2</sub>-induced senescence in human umbilical vein endothelial cells by activating the NRF2/HO-1 axis.

Blood cells, molecules & diseases·2026
Same journal

Is it time to implement a hemorheology passport in sickle cell disease?

Blood cells, molecules & diseases·2026
Same journal

From blood viscosity to a hemorheology passport: Making sickle-cell monitoring clinically actionable.

Blood cells, molecules & diseases·2026
Same journal

A real-world analysis of polycythemia vera at two comprehensive cancer centers in Cali, Colombia.

Blood cells, molecules & diseases·2026
Same journal

Sickle Cell Disease: Can genetic variability influence pregnancy outcomes?

Blood cells, molecules & diseases·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Thrombophilic polymorphisms in Israel.

Avshalom Zoossmann-Diskin1, Ephraim Gazit, Leah Peleg

  • 1Department of Haematology and Genetic Pathology, School of Medicine, Flinders University, Adelaide, Australia. avshalom.zoossmann-diskin@flinders.edu.au

Blood Cells, Molecules & Diseases
|June 28, 2008
PubMed
Summary
This summary is machine-generated.

Genetic variations linked to blood clotting (FV G1691A, FII G20210A, MTHFR C677T) show significant frequency differences in Israeli populations. High frequencies of FV G1691A and FII G20210A warrant clinical investigation for thrombosis risk.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Related Experiment Videos

Last Updated: Jul 4, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Area of Science:

  • Genetics
  • Molecular Biology
  • Population Genetics

Background:

  • Thrombophilic polymorphisms are genetic factors influencing blood clot formation.
  • Previous studies indicate genetic diversity within Israeli populations.
  • Understanding allele frequencies is crucial for assessing disease risk.

Purpose of the Study:

  • To investigate the frequencies of three key thrombophilic polymorphisms (FV G1691A, FII G20210A, MTHFR C677T) in various Israeli populations.
  • To analyze the genetic relatedness of Jewish populations to non-Jewish populations based on these polymorphisms.

Main Methods:

  • Real-time PCR with fluorescence resonance energy transfer (FRET) was employed for genotyping.
  • Allele frequencies were calculated for each polymorphism across different Israeli ethnic groups.
  • Principal Coordinates Analysis was used for population genetic comparisons.

Main Results:

  • Significant variability in the allele frequencies of FV G1691A, FII G20210A, and MTHFR C677T was observed among Israeli populations.
  • Notably high allele frequencies for FV G1691A (up to 0.087) and FII G20210A (up to 0.061) were found in specific Jewish subgroups.
  • Principal Coordinates Analysis showed Jewish populations interspersed among non-Jewish populations, suggesting genetic similarities.

Conclusions:

  • The high frequencies of FV G1691A and FII G20210A in certain Israeli populations suggest a potential clinical significance for venous thrombosis risk.
  • Genetic profiling reveals complex interrelationships between Jewish and non-Jewish populations, aligning with classical genetic marker studies.